Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 14/20 | 0.74 |
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.64 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.58 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.58 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.56 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.56 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.56 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1745405 | 0.90 | FFAR1 (0.83) | FFAR1FFAR4PTGER4PTGER3 | |
| SCHEMBL2000659 | 0.89 | FFAR1 (0.71) | FFAR1FFAR4 | |
| SCHEMBL3917744 | 0.88 | FFAR1 (0.60) | FFAR1FFAR4S1PR1S1PR5 | |
| SCHEMBL10635192 | 0.86 | FFAR1 (0.66) | FFAR1FFAR4PTGER4PTGER3 | |
| SCHEMBL3914337 | 0.86 | S1PR1 (0.60) | FFAR1FFAR4S1PR1S1PR5 | |
| SCHEMBL1745115 | 0.85 | FFAR1 (1.00) | FFAR1FFAR4 | |
| SCHEMBL7910887 | 0.84 | FFAR1 (0.64) | FFAR1FFAR4PTGER4PTGER3PTGER1 | |
| SCHEMBL16354323 | 0.84 | FFAR1 (0.68) | FFAR1FFAR4 | |
| SCHEMBL19266435 | 0.84 | FFAR1 (0.56) | FFAR1FFAR4S1PR1S1PR5 | |
| SCHEMBL16354338 | 0.84 | FFAR1 (0.77) | FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932289-B2 | Remedy for diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7820837-B2 | ethyl {6-[(3-phenoxybenzyl)oxy]-3,4-dihydronaphthalen-1-yl}acetate; having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20080319077-A1 | Remedy for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-12-25 | — | — | US | disclosed |
| EP-0503563-B1 | Novel 8-substituted purines as selective adenosine receptor agents | MERRELL PHARMA INC (US) | 2003-09-17 | — | — | EP | disclosed |
| US-5208240-A | Alzeheimer's, cardiovascular, respiratory | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-05-04 | — | — | US | disclosed |
| EP-0503563-A2 | Novel 8-substituted purines as selective adenosine receptor agents | MERRELL PHARMACEUTICALS INC. (US) | 1992-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319077-A1 | Remedy for Diabetes | GPR119, GLP1R, GPR65 | FFAR1 19/4885FFAR4 22/4885S1PR1 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.